Discover a convenient single-dose, in-clinic treatment for canine otitis externa. With a novel combination of active ingredients, this treatment provides the best of 3 worlds.

Product Label

Modified for demonstration only. Do not remove top of box.

Overview

Technical

Features & Benefits of Mometamax Single™

Unique Indication

The only single-dose treatment approved to treat Pseudomonas aeruginosa

More Options

A simple solution when in-clinic administration is best

Triple Action

Antibacterial, antifungal, and anti-inflammatory formula

Long-lasting Relief

Highly effective for more than 4 weeks1

Novel Combination of 3 Trusted Ingredients

One dose of Mometamax Single delivers the broadest spectrum of activity available for in-clinic use.

Product Specifications

Administration

Designed with a dog’s ear anatomy in mind, the 0.8-mL dose uses the flow of gravity to coat the external ear canal.

Indication

Mometamax Single is indicated for the treatment of otitis externa associated with susceptible strains of yeast (Malassezia pachydermatis) and bacteria (Staphylococcus pseudintermedius and Pseudomonas aeruginosa) in dogs.  

Supplied

Multidose vial contains 20 doses, and packaging includes 20 single-use syringes for administration. No refrigeration needed.

Safety

One-dose treatment is effective, well-tolerated, and proven safe in dogs.1

Unique Ingredients Deliver Unmatched Benefits

Make Mometamax Single™ your first choice for in-clinic otitis treatment.

All trademarks are property of their respective owners.

Relief That Delivers on Safety

Reliable efficacy in a single 0.8-mL dose.

Well-tolerated1

There were no adverse reactions directly attributable to administration of Mometamax Single.

Normal lab results1

No clinically relevant treatment-related findings were noted in blood work and urinalysis.*

No ototoxicity seen1

No ototoxicity was seen when dosed up to 5x the labeled dose every 2 weeks for 3 doses.

*Dogs were administered a series of 3 doses of Mometamax Single (0.8 mL) at 2-week intervals for the study.

Update Your In-Clinic Treatment

‡Highest percentage of treatment success at the respective study end point compared with any other in-clinic otitis treatment

§Compared with control dogs

How to Apply

Clean and dry the external ear canal. Shake the bottle vigorously for 15 seconds before each application.

Remove the cap from the bottle, and insert the syringe with the attached adapter by pressing it firmly into the top of the bottle using the attached syringe.

Invert the bottle and draw up 0.8-mL. Leave adapter in the bottle.

Place the tip of the syringe at the entrance of the external ear canal and administer the 0.8-mL dose. The applied dose will flow into the ear canal.

After application, gently massage the base of the ear to ensure distribution of the product, and restrain the dog to minimize head shaking.  Use a new syringe for each affected ear.*

*See Prescribing Information for full administration instructions.

Downloads

MOMETAMAX SINGLE OVERVIEW SHEET

Download this PDF to print or share as a helpful resource on the benefits of Mometamax Single.

Download

Disease Information

Otitis externa is inflammation of the external ear canal. It is a common problem that affects nearly 13% of dogs.11

  • Inflammation/reddening (erythema)
  • Scratching/itching (pruritus)
  • Head shaking
  • Heat
  • Pain
  • Foul smell (malodor) from the ear
  • Discharge (inflammatory exudate) present in and around the external ear canal
  • Hearing loss

Primary causes that incite inflammation:

  • Atopic dermatitis
  • Adverse food reaction
  • Hypothyroidism
  • Parasites
  • Masses or neoplasia

Most dogs develop otitis externa because of allergies to environmental substances. The allergic reaction makes the ear itchy. Dogs respond by scratching, which damages the lining of the ear canal. Yeast and bacteria then seize the opportunity and infect the skin.

Predisposing factors that increase the risk of otitis externa:

  • Conformation: Stenotic canals, pendulous pinnae, hair overgrowth
  • Moisture: Swimming, hot/humid climates

Chronic pathological changes can occur when the primary cause of otitis externa is not well controlled, further perpetuating the disease.

EXPLORE OUR FULL RANGE OF OPTIONS FOR TREATING OTITIS EXTERNA.

Learn More

Important Safety Information

Mometamax SingleTM is for otic use in dogs only. Do not use in cats. Mometamax Single should be administered by veterinary personnel. Do not use in dogs with known tympanic membrane perforation. The integrity of the tympanic membrane should be confirmed before administering the product. Reevaluate the dog if hearing loss or signs of vestibular dysfunction are observed during treatment. Do not use in dogs with known or suspected hypersensitivity to gentamicin, posaconazole, or mometasone furoate. Avoid contact with eyes. For complete instructions and safety information, refer to the product label.

References:

  1.  Mometamax Single. Product label. Merck Animal Health; 2025.
  2. Bourdeau P, Marchand AM, Etore F. In vitro activity of posaconazole and other antifungals against Malasszia pachydermatis isolated from dogs. Vet Dermatol. 2004;15:46. doi:10.1111/j.1365-3164.2004.00414_17.x
  3. Paterson S. Topical ear treatment – options, indications, and limitations of current therapy. J Small Anim Pract. 2016;57:668-678.
  4. Lyskova P, Vydrazalova M, Mazurova J. Identification and antimicrobial susceptibility of bacteria and yeasts isolated from healthy dogs and dogs with otitis externa. J Vet Med A Physiol Pathol Clin Med. 2007;54(10):559-563.
  5. Ludwig C, de Jong A, Moyaert H, et al. Antimicrobial susceptibility monitoring of dermatological bacterial pathogens isolated from diseased dogs and cats across Europe (ComPath results). J Appl Microbiol. 2016;121(5):1254-1267. doi:10.1111/jam.13287
  6. Bourély C, Cazeau G, Jarrige N, et al. Antimicrobial resistance patterns of bacteria isolated from dogs with otitis. Epidemiol Infect. 2019;147:e121. doi:10.1017/S0950268818003278
  7. Peano A, Johnson E, Chiavassa E, Tizzani P, Guillot J, Pasquetti M. Antifungal resistance regarding Malassezia pachydermatis: Where are we now?  J Fungi. 2020;6(2):93. doi:10.3390/jof6020093
  8. Claro. Package insert. Elanco; 2022.
  9. Osurnia. Package insert. Dechra; 2022.
  10. Freedom of Information Summary, NADA 141-600.
  11. State of Pet Health® 2016 Report. Banfield Pet Hospital. Accessed April 7, 2025. www.banfield.com/state-of-pet-health
  12. Nuttall T. Managing recurrent otitis externa in dogs: what have we learned and what can we do better? J Am Vet Med Assoc. 2023;261(S1):S10-S22. doi:10.2460/javma.23.01.0002
  13. Petrov V, Zhelev G, Marutsov P, et al. Microbiological and antibacterial resistance profile in canine otitis externa – a comparative analysis. Bulg J Vet Med. 2019;22(4):447-456. doi:10.15547/bjvm.2151
  14. Zur G, Lifshitz B, Bdolah-Abram T. The association between signalment, common causes of canine otitis externa and pathogens. J Small Anim Pract. 2011;52(5):254-258. doi:10.1111/j.1748-5827.2011.01058.x
  15. Oliveria LC, Leite CA, Brilhante RS, Carvalho CB. Comparative study of the microbial profile from bilateral canine otitis externa. Can Vet J. 2008;49(8):785-788.